Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer
| Autor: | Karl H. Pang, Aidan P. Noon |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Urology medicine.medical_treatment Bladder tumour 030232 urology & nephrology Review Article Resection Cystectomy 03 medical and health sciences 0302 clinical medicine medicine Carcinoma primary cystectomy non-muscle invasive bladder cancer (NMIBC) Bladder cancer business.industry Gold standard Muscle invasive medicine.disease Immediate radical cystectomy Reproductive Medicine 030220 oncology & carcinogenesis bladder cancer business Non muscle invasive |
| Zdroj: | Translational Andrology and Urology |
| ISSN: | 2223-4691 2223-4683 |
| DOI: | 10.21037/tau.2018.09.06 |
| Popis: | Bladder cancer (BC) is a common disease in both sexes and majority of cases present as non-muscle invasive BC (NMIBC). The percentage of NMIBC progressing to muscle invasive BC (MIBC) varies between 25% and 75% and currently there are no reliable molecular markers that may predict the outcome of high-risk (HR) NMIBC. Transurethral resection of the bladder tumour (TURBT) with intravesical bacillus Calmette-Guérin (BCG) or immediate radical cystectomy (RC) are the current gold standard treatment options. The European Association of Urology (EAU) guidelines recommend immediate or delayed RC for HR- and a subgroup of “highest-risk” NMIBC. These cases include pT1, carcinoma in-situ (CIS), multifocal disease, histological variants such as micropapillary and sarcomatoid, and patients who have contraindications to, or have failed with BCG. The comparative risks between maintenance BCG (mBCG) and immediate RC are unclear. However, RC may give patients the best oncological outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|